87 related articles for article (PubMed ID: 14977050)
21. [Research on Parvovirus B19 infections and chronic articular manifestations in a Tunisian hospital].
Regaya F; Khelifa R; Zouari R; Kchir M; Karoui M; Essid R
Arch Inst Pasteur Tunis; 2003; 80(1-4):9-15. PubMed ID: 15941063
[TBL] [Abstract][Full Text] [Related]
22. Parvovirus B19 may have a role in the pathogenesis of juvenile idiopathic arthritis.
Gonzalez B; Larrañaga C; León O; Díaz P; Miranda M; Barría M; Gaggero A
J Rheumatol; 2007 Jun; 34(6):1336-40. PubMed ID: 17477467
[TBL] [Abstract][Full Text] [Related]
23. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection.
Lindner J; Barabas S; Saar K; Altmann D; Pfister A; Fleck M; Deml L; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):356-61. PubMed ID: 16316401
[TBL] [Abstract][Full Text] [Related]
24. Concurrent detection of human herpesvirus type 6 and measles-specific IgMs during acute exanthematic human parvovirus B19 infection.
Navalpotro D; Gimeno C; Navarro D
J Med Virol; 2006 Nov; 78(11):1449-51. PubMed ID: 16998885
[TBL] [Abstract][Full Text] [Related]
25. Standardization of parvovirus B19 DNA extraction from serum and quantitative PCR.
Kishore J
Indian J Pathol Microbiol; 2005 Oct; 48(4):522-5. PubMed ID: 16366117
[TBL] [Abstract][Full Text] [Related]
26. IgE, CD8(+)CD60+ T cells and IFN-alpha in human immunity to parvovirus B19 in selective IgA deficiency.
Bluth MH; Norowitz KB; Chice S; Shah VN; Nowakowski M; Durkin HG; Smith-Norowitz TA
Hum Immunol; 2005 Oct; 66(10):1029-38. PubMed ID: 16386644
[TBL] [Abstract][Full Text] [Related]
27. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
28. Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis.
Kerr JR; Cunniffe VS; Kelleher P; Coats AJ; Mattey DL
J Med Virol; 2004 Sep; 74(1):147-55. PubMed ID: 15258981
[TBL] [Abstract][Full Text] [Related]
29. An assay for parvovirus B19 neutralizing antibodies based on human hepatocarcinoma cell lines.
Caillet-Fauquet P; Di Giambattista M; Draps ML; Hougardy V; de Launoit Y; Laub R
Transfusion; 2004 Sep; 44(9):1340-3. PubMed ID: 15318858
[TBL] [Abstract][Full Text] [Related]
30. The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production.
Tzang BS; Tsay GJ; Lee YJ; Li C; Sun YS; Hsu TC
Clin Chim Acta; 2007 Mar; 378(1-2):59-65. PubMed ID: 17169353
[TBL] [Abstract][Full Text] [Related]
31. Human parvovirus B19 virus-like particles: In vitro assembly and stability.
Sánchez-Rodríguez SP; Münch-Anguiano L; Echeverría O; Vázquez-Nin G; Mora-Pale M; Dordick JS; Bustos-Jaimes I
Biochimie; 2012 Mar; 94(3):870-8. PubMed ID: 22192916
[TBL] [Abstract][Full Text] [Related]
32. Noninfectious virus-like particle antigen for detection of swine vesicular disease virus antibodies in pigs by enzyme-linked immunosorbent assay.
Ko YJ; Choi KS; Nah JJ; Paton DJ; Oem JK; Wilsden G; Kang SY; Jo NI; Lee JH; Kim JH; Lee HW; Park JM
Clin Diagn Lab Immunol; 2005 Aug; 12(8):922-9. PubMed ID: 16085909
[TBL] [Abstract][Full Text] [Related]
33. Parvovirus B19 VP2-proteins produced in Saccharomyces cerevisiae: comparison with VP2-particles produced by baculovirus-derived vectors.
Lowin T; Raab U; Schroeder J; Franssila R; Modrow S
J Vet Med B Infect Dis Vet Public Health; 2005; 52(7-8):348-52. PubMed ID: 16316399
[TBL] [Abstract][Full Text] [Related]
34. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
Revaz V; Zurbriggen R; Moser C; Schiller JT; Ponci F; Bobst M; Nardelli-Haefliger D
Antiviral Res; 2007 Oct; 76(1):75-85. PubMed ID: 17617476
[TBL] [Abstract][Full Text] [Related]
35. Recurrent high level parvovirus B19/genotype 2 viremia in a renal transplant recipient analyzed by real-time PCR for simultaneous detection of genotypes 1 to 3.
Liefeldt L; Plentz A; Klempa B; Kershaw O; Endres AS; Raab U; Neumayer HH; Meisel H; Modrow S
J Med Virol; 2005 Jan; 75(1):161-9. PubMed ID: 15543575
[TBL] [Abstract][Full Text] [Related]
36. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.
Bessa J; Schmitz N; Hinton HJ; Schwarz K; Jegerlehner A; Bachmann MF
Eur J Immunol; 2008 Jan; 38(1):114-26. PubMed ID: 18081037
[TBL] [Abstract][Full Text] [Related]
37. Purification and analysis of polyhistidine-tagged human parvovirus B19 VP1 and VP2 expressed in insect cells.
Michel PO; Mäkelä AR; Korhonen E; Toivola J; Hedman L; Söderlund-Venermo M; Hedman K; Oker-Blom C
J Virol Methods; 2008 Sep; 152(1-2):1-5. PubMed ID: 18598721
[TBL] [Abstract][Full Text] [Related]
38. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
39. Endothelin receptor in virus-like particles: ligand binding observed by fluorescence fluctuation spectroscopy.
Zemanová L; Schenk A; Hunt N; Nienhaus GU; Heilker R
Biochemistry; 2004 Jul; 43(28):9021-8. PubMed ID: 15248759
[TBL] [Abstract][Full Text] [Related]
40. Clinical interpretation of antineutrophil cytoplasmic antibodies: parvovirus B19 infection as a pitfall.
Hermann J; Demel U; Stünzner D; Daghofer E; Tilz G; Graninger W
Ann Rheum Dis; 2005 Apr; 64(4):641-3. PubMed ID: 15485998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
